TPEXTREME RANDOMIZED TRIAL PUBLISHED IN LANCET

Michelle Gill
Mar 10, 2023
1 min read

April 2021

Taxane-based TPEx regimen appears to be a new option in first line recurrent/metastatic HNSCC, with a shorter time on therapy and lower toxicity than the reference EXTREME regimen. This can provide an alternative to SOC with EXTREME regimen, especially for those who may not be good candidates for up-front pembrolizumab. https://pubmed.ncbi.nlm.nih.gov/33684370/

Recent Posts

See All

HNCIG-EPIC-OPC: PROGNOSTIC IMPLICATIONS OF P16 AND HPV DISCORDANCE: A MULTINATIONAL ANALYSIS, PUBLISHED IN LANCET ONCOLOGY

https://pubmed.ncbi.nlm.nih.gov/36796393/

HNCIG-ENDORSED RECOMMENDATIONS FOR POST-OP RT IN HNSCC IN PRESENCE OF FLAPS PUBLISHED BY GORTEC

https://pubmed.ncbi.nlm.nih.gov/33984351/

HNCIG CONSENSUS ON ENDPOINT DEFINITIONS IN CURATIVE-INTENT TRIALS FOR HNSCC PUBLISHED IN LANCET ONCOLOGY

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00067-6/fulltext